Iranian journal of kidney diseases最新文献_第3页

Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway. 神气丸通过削弱Notch1/Jag1通路缓解肾间质纤维化

IF 0.8 4区医学

Iranian journal of kidney diseases Pub Date : 2024-05-01 DOI: 10.52547/b56av842

Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng

{"title":"Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway.","authors":"Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng","doi":"10.52547/b56av842","DOIUrl":"10.52547/b56av842","url":null,"abstract":"Introduction: Shenqi pill (SQP) can be used to treat various kidney related diseases, but its exact mechanism of action remains unclear. We intended to analyze the role and mechanism of SQP on renal interstitial fibrosis (RIF).Methods: After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.Results: SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).Conclusion: Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"18 3","pages":"159-167"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/0zev2y05

Admin Admin

引用次数: 0

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/dt6zs176

Azin Ghaffari, Mitra Mehrazma, Shahrzad Ossareh

引用次数: 0

Attenuating Renal Interstitial Fibrosis by Shenqi Pill via Reducing Inflammation Response Regulated by NF-κB Pathway In Vitro and In Vivo. 神气丸通过降低体外和体内 NF-κB 通路调控的炎症反应减轻肾间质纤维化

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/kv5ap920

Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng

引用次数: 0

Risk Factors and Clinical Characterization of Cardiovascularand Cerebrovascular Events in Elderly Hemodialysis Patients. 老年血液透析患者心脑血管事件的风险因素和临床特征。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/r2vqgm28

Wei Liu, Hong Ze Wang, Ying Shi, Weiqiang Shen, Mingyan Dai

引用次数: 0

Conceptual Approach to Body Fluids and Edema, Education Determines Clinical Outcomes in Heart Failure. 体液和水肿的概念方法，教育决定心力衰竭的临床结果。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/1aytkx77

Mohammad A Shafiee, Amireza Goli, Pouyan Shaker, Vishal Sharma, Yasmin Shahideh, Khrystyna Maryniak, Behrooz Broumand

引用次数: 0

Microvesicles from Mesenchymal Stem Cells Overexpressing MiR-34a Ameliorate Renal Fibrosis In Vivo. 过表达 MiR-34a 的间充质干细胞微囊可改善体内肾脏纤维化

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/s9bdqs74

Yan Wang, Ping Hu, Yangping Li, Ruijuan Dong, Juan He

{"title":"Microvesicles from Mesenchymal Stem Cells Overexpressing MiR-34a Ameliorate Renal Fibrosis In Vivo.","authors":"Yan Wang, Ping Hu, Yangping Li, Ruijuan Dong, Juan He","doi":"10.5254/s9bdqs74","DOIUrl":"https://doi.org/10.5254/s9bdqs74","url":null,"abstract":"We recently discovered that microvesicles (MVs) derived from mesenchymal stem cells (MSCs) overexpressing miRNA-34a can alleviate experimental kidney injury in mice. In this study, we further explored the effects of miR34a-MV on renal fibrosis in the unilateral ureteral obstruction (UUO) models. Methods. Bone marrow MSCs were modified by lentiviruses overexpressing miR-34a, and MVs were collected from the supernatants of MSCs. C57BL6/J mice were divided into control, unilateral ureteral obstruction (UUO), UUO + MV, UUO + miR-34aMV and UUO + miR-34a-inhibitor-MV groups. MVs were injected to mice after surgery. The mice were then euthanized on day 7 and 14 of modeling, and renal tissues were collected for further analyses by Hematoxylin and eosin, Masson's trichrome, and Immunohistochemical (IHC) staining. Results. The UUO + MV group exhibited a significantly reduced degree of renal interstitial fibrosis with inflammatory cell infiltration, tubular epithelial cell atrophy, and vacuole degeneration compared with the UUO group. Surprisingly, overexpressing miR-34a enhanced these effects of MSC-MV on the UUO mice. Conclusion. Our study demonstrates that miR34a further enhances the effects of MSC-MV on renal fibrosis in mice through the regulation of epithelial-to-mesenchymal transition (EMT) and Notch pathway. miR-34a may be a candidate molecular therapeutic target for the treatment of renal fibrosis. DOI: 10.52547/ijkd.7673.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"9 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140801461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind the Gap in Kidney Care: Translating What We Know Into What We Do. 关注肾脏护理中的差距：将我们的知识转化为我们的行动。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/sqbbj216

Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci, Or The World Kidney Day Joint Steering Committee

{"title":"Mind the Gap in Kidney Care: Translating What We Know Into What We Do.","authors":"Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci, Or The World Kidney Day Joint Steering Committee","doi":"10.5254/sqbbj216","DOIUrl":"https://doi.org/10.5254/sqbbj216","url":null,"abstract":"Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay. DOI: 10.52547/ijkd.8216.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"50 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140806280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor. PD-1/PD-L1抑制剂治疗的原发性非小细胞肺癌患者发生AKI的风险因素分析

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/0n3xpz60

Jiong-Ming Ying, Feng Yan

引用次数: 0

Correlation Between the 8-hydroxy-2'-deoxyguanosine Level in the Peritoneal Solution of Patients Undergoing Peritoneal Dialysis and the Peritoneal Equilibration Test, Kt/V, Ferritin, and Albumin Levels. 腹膜透析患者腹腔液中 8- 羟基-2'-脱氧鸟苷水平与腹膜平衡试验、Kt/V、铁蛋白和白蛋白水平之间的相关性。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/fte08z03

Hadi Khanifar, Leila Mahmoodnia

引用次数: 0